Pacylex News
Zelenirstat Disrupts Oxidative Phosphorylation in Cancer Cells at AACR 2024
Pacylex announces that new data demonstrating that zelenirstat, a proprietary, potent, NMTi, reduces Complex I formation and oxidative phosphorylation in the mitochondria of cancer cells, will be presented at the American Association for Cancer Research (AACR) Annual Meeting from April 5-10, 2024, in San Diego, California. This new insight may help account for the effect zelenirstat had on refractory/ relapsed (r/r) cancers in a recent Phase 1 study whose results are also presented.
A poster will be presented describing the Company’s Phase 1 study safety results and efficacy signals, as well as evidence for profound disruption of Complex I formation in mitochondria of cancer cell with concomitant loss of oxidative phosphorylation. The Company’s CEO, Dr. Michael Weickert, will be available during the poster session and for one-on-one meetings. The details of the poster are below:
